Node-positive cancer downstaged by chemotherapy — clipped-node targeted dissection, ultrasound triage and omission numbers

Model answer

(A) Accuracy baseline and clipped-node rescue (5 marks)

• Stage the timing honestly: sentinel biopsy before chemotherapy detects 99.1% reliably, while after cN+ to ycN0 conversion detection falls to 80.1% with false-negative rate 14.2% — reliable before, degraded after.^[13]
• Stratify by nodes removed: false-negative rate 24.3% with one node and 18.5% with two nodes in the converted arm — remove more than one sentinel node.^[13]
• State the Z1071 baseline: false-negative rate 12.6% with sentinel surgery after chemotherapy in node-positive disease, in T0-T4 N1-N2 patients undergoing sentinel surgery plus dissection after chemotherapy.^[12]
• Rescue with the clip: clipped node in the sentinel specimen gives false-negative rate 6.8%, stranded in the dissection specimen gives 19.0% — clip placement with removal during sentinel surgery reduces the false-negative rate.^[12]
• Define TAD as sentinel dissection plus iodine-seed localisation with selective clipped-node removal; sentinel-alone false-negative rate 10.1% falls to 1.4% with the clipped node, and TAD with dissection gives 2.0% — while 23% of clipped nodes lie outside the sentinel packet including six with negative sentinels but clipped-node metastasis.^[14]

(B) Post-chemotherapy ultrasound interpretation (2 marks)

• Set the base rate: residual nodal disease in 61.0% with complete nodal response in 39.0% across 611 post-chemotherapy ultrasounds — most converted axillae still harbour disease.^[16]
• Apply cortex and morphology: cortical thickness 3.5 mm versus 2.5 mm marks residual disease; type I-II carry the lowest residual rate at 56.0-56.1% while type VI carries the highest at 80.0%; absence of fatty hilum marks residual disease — her type VI hilum-less node sits at the highest-risk end.^[16]

(C) Omission after downstaging (3 marks)

• Quote the downstaging cohort: 1144 stage II-III biopsy-proven node-positive cancers across 25 centres, with clipped-node retrieval 97% by TAD versus 86% by sentinel surgery without localisation.^[15]
• Quote the omission outcomes: 5-year axillary 1.0%, locoregional 2.7% and any invasive 10% recurrence, with 3-year axillary recurrence 0.5% versus 0.8% for TAD versus sentinel surgery — rare and not significantly lower with TAD, supporting omission in this population.^[15]